November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
13 citations
,
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Four drugs were found that could potentially treat COVID-19 by inhibiting the virus in lab tests.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
69 citations
,
February 2021 in “PLoS Computational Biology” Securinine and ajmaline may effectively treat liver cancer, with securinine being less toxic to normal cells.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
2 citations
,
August 2002 in “British Journal of Ophthalmology” Tangent screens help detect visual field defects from vigabatrin.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
3 citations
,
January 2025 in “SAGE Open Medical Case Reports” Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology” 508 citations
,
June 2009 in “Current drug metabolism” Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
October 1990 in “Pediatric Research” Nocturnal calcium infusions improved a boy's severe rickets without causing hair loss.
August 2021 in “Revista Colombiana de Reumatología/Revista Colombiana de Reumatologia” Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
4 citations
,
September 2018 in “The Journal of Dermatology” A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
44 citations
,
May 1998 in “PubMed” The retinoid receptor antagonist effectively disrupts vitamin A-related development in embryos.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
1 citations
,
October 2025 in “Scientific Reports” Sonidegib and vismodegib have different side effects and reporting patterns.
January 2008 in “Projeto: revista mensal de arquitetura” Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
9 citations
,
February 2012 in “Cancer Chemotherapy and Pharmacology” The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.
November 2005 in “Reactions Weekly” A man treated with gefitinib for lung cancer grew new hair on his bald scalp.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.